| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/14651858.CD012198 |
| P50 | author | Kah Keng Wong | Q57051808 |
| Md Asiful Islam | Q57885931 | ||
| Fahmida Alam | Q57934980 | ||
| Azlan Husin | Q57935477 | ||
| Teguh Haryo Sasongko | Q42622256 | ||
| Siew Hua Gan | Q42700244 | ||
| P2093 | author name string | Sarimah Abdullah | |
| P2860 | cites work | Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia | Q24194917 |
| The mechanism of action of aspirin | Q28165886 | ||
| Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects | Q28174152 | ||
| Platelet-active drugs : the relationships among dose, effectiveness, and side effects | Q28175147 | ||
| Management of thrombosis in antiphospholipid antibody syndrome | Q28188666 | ||
| Cyclooxygenase inhibitors and the antiplatelet effects of aspirin | Q28191912 | ||
| Antiphospholipid syndrome: an evolving story | Q28194689 | ||
| A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons | Q28253560 | ||
| Pathophysiology of the antiphospholipid syndrome | Q28267421 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects | Q28319507 | ||
| Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range | Q31828961 | ||
| Antiphospholipid antibodies and thrombosis | Q33328585 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| New anticoagulants for treatment of venous thromboembolism. | Q33362375 | ||
| Diagnosis and classification of the antiphospholipid syndrome | Q33412887 | ||
| Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients | Q33412915 | ||
| Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia | Q33419674 | ||
| Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients | Q33438663 | ||
| Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects | Q33438731 | ||
| Antibodies to serine proteases in the antiphospholipid syndrome | Q33670367 | ||
| International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop | Q33685960 | ||
| Aspirin. | Q33861695 | ||
| Edoxaban: an update on the new oral direct factor Xa inhibitor | Q33935409 | ||
| Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q34012421 | ||
| Apixaban or enoxaparin for thromboprophylaxis after knee replacement | Q34018819 | ||
| Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial | Q34134664 | ||
| beta2-glycoprotein i is a cofactor for tissue plasminogen activator-mediated plasminogen activation | Q34245642 | ||
| Mechanism of the anticoagulant action of heparin | Q34268523 | ||
| Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects | Q34285711 | ||
| The influence of omeprazole on platelet inhibition of clopidogrel in various CYP2C19 mutant alleles | Q34304663 | ||
| The pathogenesis of the antiphospholipid syndrome | Q34332601 | ||
| 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends | Q34400373 | ||
| Rivaroxaban: a new oral factor Xa inhibitor | Q34616521 | ||
| The mechanism of action of rivaroxaban – an oral, direct Factor Xa inhibitor – compared with other anticoagulants | Q34624001 | ||
| Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action | Q34647850 | ||
| Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2 | Q34803113 | ||
| Guidelines for the treatment of antiphospholipid syndrome | Q34821893 | ||
| Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development | Q34900298 | ||
| Acetylation of prostaglandin synthase by aspirin | Q35085661 | ||
| Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin | Q57243326 | ||
| Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients | Q57907773 | ||
| Rapidity and duration of platelet suppression by enteric-coated aspirin in healthy young men | Q67730473 | ||
| The management of thrombosis in the antiphospholipid-antibody syndrome | Q72619159 | ||
| Proceedings of the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: evidence-based guidelines | Q80597125 | ||
| Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients | Q81670366 | ||
| Antiphospholipid syndrome (Hughes syndrome): 10 clinical topics | Q83954275 | ||
| Multiple antiphospholipid antibodies positivity and antiphospholipid syndrome criteria re-evaluation | Q85325207 | ||
| New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome | Q87417887 | ||
| Antiphospholipid syndrome: pathogenic mechanisms | Q35172006 | ||
| Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. | Q35925359 | ||
| Liver transplantation in a patient with primary antiphospholipid syndrome and Budd-Chiari syndrome | Q36033553 | ||
| Successful Treatment of Livedoid Vasculitis with Primary Antiphospholipid Syndrome by Using Aspirin and Low Dose Warfarin Combination Therapy | Q36214271 | ||
| Inhibition of platelet prostaglandin synthetase by oral aspirin | Q37050575 | ||
| Antiplatelet and anticoagulant agents: key differences in mechanisms of action, clinical application, and therapeutic benefit in patients with non-ST-segment-elevation acute coronary syndromes | Q37180484 | ||
| Simultaneous intrahepatic and subgaleal hemorrhage in antiphospholipid syndrome following anticoagulation therapy | Q37233852 | ||
| Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome | Q37283006 | ||
| Platelets and the antiphospholipid syndrome | Q37283013 | ||
| Resistance to annexin A5 anticoagulant activity: a thrombogenic mechanism for the antiphospholipid syndrome | Q37283029 | ||
| Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome | Q37283036 | ||
| Tissue factor in the antiphospholipid syndrome | Q37283046 | ||
| Venous thrombosis in the antiphospholipid syndrome | Q37396639 | ||
| New oral anticoagulants | Q37843749 | ||
| Mechanism of heparin action | Q37902486 | ||
| Pharmacokinetics of heparin and low molecular weight heparin | Q37902488 | ||
| Guidelines on the investigation and management of antiphospholipid syndrome | Q37982121 | ||
| Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment | Q38079779 | ||
| Management of recurrent thrombosis in antiphospholipid syndrome | Q38180647 | ||
| Edoxaban, a Novel Oral Factor Xa Inhibitor | Q38412381 | ||
| Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. | Q38416654 | ||
| Organ Damage and Quality of Life in Antiphospholipid Syndrome. | Q38697342 | ||
| Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. | Q40032766 | ||
| Direct oral anticoagulants in antiphospholipid syndrome: a real life case series | Q40131133 | ||
| Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS). | Q40323287 | ||
| Vitamin K and the oral anticoagulant drugs | Q40553146 | ||
| Human P450 metabolism of warfarin | Q41334623 | ||
| Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis | Q41570554 | ||
| Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers | Q42635960 | ||
| Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". | Q44550364 | ||
| A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome | Q44588720 | ||
| Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. | Q45173221 | ||
| Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans | Q46131621 | ||
| Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects | Q46835939 | ||
| The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans | Q46897672 | ||
| Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. | Q50619255 | ||
| Tissue Distribution and Elimination of [14C]Apixaban in Rats | Q51533087 | ||
| P921 | main subject | anticoagulant | Q215118 |
| thrombosis | Q261327 | ||
| antiphospholipid syndrome | Q582207 | ||
| anticoagulation | Q63279445 | ||
| P577 | publication date | 2016-05-17 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Antiplatelet and anticoagulant agents for preventing recurrence of peripheral vascular thrombosis in patients with Antiphospholipid syndrome |
| Q47884958 | Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. | cites work | P2860 |
Search more.